170 completed. 170 Phase 2, 24 Phase 1, 13 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 170 | Completed 170 |
| Phase 1 | 24 | Completed 24 |
| Phase 3 | 13 | Completed 13 |
Follow Glaucoma: new trials by email Literature Review of Glaucoma trials Research Report on Glaucoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension QLS-111-FDC, Latanoprost (0.005%) - OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension | Phase 2 / Phase 3 | Completed | Qlaris Bio, Inc. | 64 | 2026-03-18 | 2026-07-29 |
| Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%) - Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG) | Phase 2 | Completed | Qlaris Bio, Inc. | 9 | 2026-02-20 | 2026-11-02 |
| Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5% - Glaucoma | Phase 2 | Completed | Bausch & Lomb Incorporated | 252 | 2025-10-24 | 2026-07-22 |
| Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG) QLS-111 ophthalmic solution (0.015%), Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) - Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral | Phase 2 | Completed | Qlaris Bio, Inc. | 37 | 2025-08-13 | 2026-04-03 |
| The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK) Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, Placebo - Pseudophakic Bullous Keratopathy, Glaucoma | Phase 2 / Phase 3 | Completed | University Hospital Dubrava | 50 | 2025-05-12 | 2026-09-09 |
| Next Generation Rocklatan AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution - Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Alcon Research | 426 | 2024-09-04 | 2025-11-18 |
| Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension T4090 0.2%, T4090 0.3%, Rhopressa® - Glaucoma, Ocular Hypertension | Phase 2 | Completed | Laboratoires Thea | 161 | 2024-08-05 | 2026-01-02 |
| Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients QLS-111, 0.015%, QLS-111, 0.030%, QLS-111, 0.075% - Open-angle Glaucoma (OAG), Ocular Hypertension (OHT) | Phase 2 | Completed | Qlaris Bio, Inc. | 36 | 2024-04-21 | 2025-01-20 |
| Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients Experimental: QLS-111 ophthalmic solution, (0.015%), Experimental: QLS-111 ophthalmic solution, (0.03%), Experimental: QLS-111 ophthalmic solution, (0.075%) - Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes | Phase 2 | Completed | Qlaris Bio, Inc. | 63 | 2024-03-05 | 2025-01-20 |
| Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution NCX 470, Placebo - Open Angle Glaucoma | Phase 2 / Phase 3 | Completed | Nicox Ophthalmics, Inc. | 18 | 2023-12-12 | 2025-09-08 |
| Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure SBI-100 Ophthalmic Emulsion, 0.5%, SBI-100 Ophthalmic Emulsion, 1.0%, SBI-100 Ophthalmic Emulsion, Placebo - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Skye Bioscience, Inc. | 56 | 2023-11-09 | 2026-01-14 |
| Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension H-1337 0.6%, H-1337 1.0%, H-1337 Placebo - Glaucoma Open-Angle Primary, Ocular Hypertension | Phase 2 | Completed | D. Western Therapeutics Institute, Inc. | 201 | 2023-08-28 | 2025-08-27 |
| A Study of PER-001 in Participants With Open-Angle Glaucoma PER-001 Intravitreal Implant - Low Dose, PER-001 Intravitreal Implant - High Dose, PER-001 Intravitreal Implant - Sham - Open-angle Glaucoma | Phase 1 / Phase 2 | Completed | Perfuse Therapeutics, Inc. | 33 | 2023-05-25 | 2026-06-05 |
| Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP) QLS-101 ophthalmic solution, 2.0 % - Sturge-Weber Syndrome, Glaucoma | Phase 2 | Completed | Qlaris Bio, Inc. | 2 | 2022-11-23 | 2025-01-20 |
| A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure VVN539 Ophthalmic Solution 0.02%, VVN539 Ophthalmic Solution 0.04%, VVN539 Ophthalmic Solution Vehicle - Glaucoma, Open-Angle | Phase 2 | Completed | VivaVision Biotech, Inc | 68 | 2022-07-12 | 2024-01-17 |
| A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT) OTX-TIC low dose Travoprost Intracameral Implant, OTX-TIC high dose Travoprost Intracameral Implant, Durysta, Bimatoprost Intracameral Implant 10 µg - Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Ocular Therapeutix, Inc. | 83 | 2022-03-16 | 2026-09-03 |
| Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG) Mexidol, Placebo - Primary Open-Angle Glaucoma (POAG) | Phase 2 | Completed | Pharmasoft | 102 | 2021-11-15 | 2025-12-12 |
| A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101 QLS-101ophthalmic solution 1%, QLS-101ophthalmic solution 2% - Sturge-Weber Syndrome (SWS), Glaucoma | Phase 2 | Completed | Qlaris Bio, Inc. | 3 | 2021-10-19 | 2025-01-20 |
| A Study to Evaluate Safety and Tolerability of QLS-101 in NTG QLS-101, Timolol maleate PF 0.5% ophthalmic solution - Normal Tension Glaucoma (NTG) | Phase 2 | Completed | Qlaris Bio, Inc. | 30 | 2021-09-15 | 2025-01-20 |
| Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension Nebivolol Ophthalmic Suspension 1 Percent, Nebivolol Ophthalmic Suspension 0.5 Percent, Timolol Ophthalmic Suspension 0.5 Percent - Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Betaliq, Inc. | 226 | 2021-04-15 | 2024-04-17 |
Showing 20 of 170. Sign in to see all of them.
Ocular Hypertension (119) · Glaucoma, Open-Angle (113) · Hypertension (6) · Low Tension Glaucoma (5) · Eye Diseases (3) · Glaucoma, Neovascular (3) · Cataract (2) · Exfoliation Syndrome (2) · Glaucoma, Angle-Closure (2) · Hydrophthalmos (2) · Sturge-Weber Syndrome (2) · Corneal Edema (1) · Diabetic Retinopathy (1) · Macular Degeneration (1)
Eye Diseases (167) · Ocular Hypertension (51) · Cardiovascular Diseases (9) · Vascular Diseases (9) · Optic Nerve Diseases (5) · Retinal Diseases (3) · Angiomatosis (2) · Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Eye Abnormalities (2) · Glaucoma, Open-Angle (2) · Hemangioma (2) · Infant, Newborn, Diseases (2) · Iris Diseases (2)
Latanoprost (33) · Bimatoprost (13) · Ophthalmic Solutions (12) · Timolol (11) · Travoprost (9) · Mitomycin (7) · netarsudil (6) · AR-12286 (5) · brinzolamide (5) · Bevacizumab (4) · Brimonidine Tartrate (4) · Hanks Balanced Salt Solution (4) · anecortave acetate (3) · dorzolamide (3) · INO-8875 (2)
Alcon Research (23) · Aerie Pharmaceuticals (15) · Allergan (10) · Mati Therapeutics Inc. (10) · Qlaris Bio, Inc. (9) · Santen Inc. (9) · Bausch & Lomb Incorporated (6) · ForSight Vision5, Inc. (5) · Glaukos Corporation (3) · Inotek Pharmaceuticals Corporation (3) · Santen Pharmaceutical Co., Ltd. (3) · Sylentis, S.A. (3) · Wills Eye (3) · Amakem, NV (2) · Hoffmann-La Roche (2)
United States (121) · Japan (6) · Germany (4) · Spain (4) · United Kingdom (4) · Austria (3) · Canada (3) · Czechia (3) · Israel (3) · Mexico (3) · Singapore (3) · Australia (2) · Belgium (2) · Brazil (2) · Bulgaria (2)
Michelle Chen, PhD (5) · Theresa Landry (4) · Lisa Brandano (3) · Oscar Cuzzani, MD (3) · Theresa Heah, MD (3) · B. Wirostko, M.D. (2) · Barbara M Wirostko, MD (2) · Marlene R Moster, MD (2) · Nancy Ramirez-Davis (2) · Oscar Cuzanni, MD, MSc (2) · Suzanne Cadden (2) · Theresa Landry, Ph.D. (2)
PMID 12049574, PMID 12365904, PMID 12472329, PMID 15885795, PMID 19049301, PMID 19850848, PMID 20570237, PMID 21257146, PMID 21794845, PMID 21851167, PMID 22332206, PMID 22607109, PMID 22835512, PMID 23377586, PMID 24212847, PMID 24248002, PMID 24504128, PMID 24513094, PMID 24794283, PMID 24974815, PMID 25019269, PMID 25826644, PMID 26209587, PMID 27310103, PMID 27312975, PMID 27457257, PMID 27649982, PMID 28528010, PMID 28957960, PMID 29189540, PMID 29802818, PMID 32533949, PMID 33244711, PMID 33629227, PMID 35076329, PMID 35167779, PMID 35643967, PMID 36055467, PMID 36912740, PMID 38060092, PMID 40043909, PMID 40126812, PMID 41832303, PMID 9261306
2008 (1), 2009 (1), 2018 (1)